Purpose Recently, microRNA-124 (miR-124) has been demonstrated as a potential tumor suppressor in several types of cancers. However, the role of miR-124 in colorectal cancer remains unclear. This study was aimed at investigating the clinicopathological significance of miR-124 expression in colorectal cancer. Methods Quantitative real-time PCR was used to analyze miR-124 expression in 96 colorectal cancers and individualmatched normal mucosa samples. The expression of miR-124 was assessed for associations with clinicopathological characteristics using chi-square test. The survival curves were calculated by the Kaplan-Meier method. The influence of each variable on survival was examined by the Cox multivariate regression analysis.
Introduction
MicroRNAs (miRNAs) are endogenous noncoding, singlestranded RNAs of ∼22 nucleotides which are involved in the regulation of human gene expression. Through base pairing with the 3′-untranslated region (3′-UTR) of target messenger RNA, miRNAs prevent gene expression by inhibiting protein translation. Several miRNAs have been reported to participate in diverse essential biological processes including: cell proliferation, apoptosis, development, and differentiation [1] . Since the first study of miRNA involvement in chronic lymphocytic leukemia in 2002 [2] , there is growing evidence that miRNAs are implicated in human carcinogenesis by functioning as either oncogenes or tumor suppressors through their interactions with target genes critical to development and progression of various cancers, including colorectal cancer [3, 4] .
Colorectal cancer is a major cause of cancer mortality worldwide [5] . It is the third most commonly diagnosed cancer and the third leading cause of cancer death in the USA [6] . In China, its incidence has increased in the past few years. In 2003, miR-143 and miR-145 were ascertained as the first two novel dysregulated miRNAs in colon cancer [7] . From then on, subsequent authors identified additional miRNAs by various screening tools and found several dysregulated miRNAs implicated in colorectal cancer. A multitude of experimental studies have described the ability of miRNAs in the detection, treatment, and prognosis of colorectal cancer [8, 9] .
Recently, as one of the most abundantly expressed miRNAs in the central nervous system, miR-124 has been shown to play a significant role in the pathogenesis of various cancers [10] [11] [12] [13] [14] [15] . Lower levels of miR-124 expression were frequently detected in hepatocellular cancer and related to tumor metastasis [15] . The downregulation of miR-124 has also been observed in gastric, cervical, and breast cancer, which may be caused by DNA methylation-based silencing [11, 16, 17] . Additionally, miR-124 has been involved in the invasion and metastasis process of hepatocellular cancer, by directly targeting the rho-kinase2 (ROCK2) and an enhancer of the zeste homologue 2 (EZH2) genes [15] . Overexpression of miR-124 attenuated integrin beta-1(ITGB1) expression and suppressed the adherence and motility of oral squamous cancer cells [14] . To date, several lines of evidence have shown that miR-124 may be a novel prognostic factor and therapeutic target for some types of cancers [12, 13, 15] . These data demonstrated the potential tumor suppressor role of miR-124; however, the relationship between expression of miR-124 and colorectal cancer remains unclear.
In the present study, we used real-time PCR to quantify the expression of miR-124 in 96 colorectal cancers and individual-matched normal mucosa samples. Furthermore, we investigated its relationship with clinicopathological features and survival in patients with colorectal cancer.
Materials and methods

Patients and tissues
All patients included in the study underwent surgical resection procedures at the Gastrointestinal Surgery Department, Affiliated West China Hospital of Sichuan University, Chengdu City, China, from July 2006 to December 2007. The eligible cases were primary colorectal cancer without preoperative radiotherapy or chemotherapy. The patients with hereditary syndromes (e.g., FAP, HNPCC) or inflammatory bowel syndromes had been excluded. The patients consisted of 54 men and 42 women with a median age of 55 years (range, 24-81 years). Once the surgical specimens were obtained, individual-matched normal mucosa adjacent to the proximal excision margin was harvested. All specimens were snap-frozen immediately in liquid nitrogen and stored in a freezer at −80°C until further analysis. The specimens were examined for the presence of tumor cells, which usually were at least around 80 %, at the Department of Pathology in the West China Hospital. The growth pattern was based on the patterns of growth and invasiveness. Differentiation was graded as well, moderately, or poorly differentiated. The study was approved by the SiChuan University Ethics Committee, and written informed consent was obtained from all the participants. As a regular follow-up program for patients with colorectal cancer, a combination of physical examination (including digital examination), blood chemistry test (including measurement of carcinoembryonic antigen levels), chest X-ray, surveillance colonoscopy, and abdominal CT was performed. At the end of 2011, the mean follow-up period was 4.33 years.
RNA extraction and cDNA synthesis For RNA extraction, frozen tissues were cut into 5-mm cubic blocks and pulverized with a mortar and pestle. RNA was isolated using TRIzol reagent (Molecular Research Center, Inc., OH, USA) according to the manufacturer's protocol. RNA was quantified at 460 nm using the spectrophotometer (Beckman Coulter, Fullerton, CA, USA); its integrity was checked by agarose gel electrophoresis. For specific quantization of mature miR-124 expression level, RNA was reverse transcribed to cDNA of miR-124 using the stem-loop RT primers (Invitrogen, Carlsbad, CA, USA; Table 1 ) which were designed according to early description [18, 19] . Total RNA (2.5 μl) was first denatured at 70°C with the 50 nM stem-loop RT primer for 5 min, and then a 10-μl reaction mix was assembled using 1 mM final of each of the four deoxynucleotide triphosphates (dNTPs), 1 U/μl RNase inhibitor, 10 U/μl M-MLV reverse transcriptase, and 1× M-MLV RT buffer (TaKaRa Biotechnology Co., Ltd, Dalian, China). The reaction proceeded for 30 min at 16°C and 30 min at 42°C followed by 5-min incubation at 85°C. To synthesize cDNA of endogenous control 5S rRNA, 5 μg of RNA was first denatured at 70°C with 2.5 mM random hexamers (TaKaRa) for 5 min before quenching on ice, and then 1 mM final of each of the four dNTPs, 1 U/μl RNAse inhibitor, 10 U/μl M-MLV reverse transcriptase, and 1× M-MLV RT buffer were added together to make up a final volume of 20 μl of reaction mix. The reaction mix was incubated using the MJ Research PTC-100TM Programmable Thermal Controller (MJ Research, MA, USA) for 10 min at 20°C and 1 h at 42°C. The reverse transcriptase was inactivated at 70°C for 10 min and then held at 4°C.
Quantitative real-time PCR
The gene-specific primers and probes for quantitative realtime PCR (Table 1) were designed using Primer Express version 2.0 (Applied Biosystems, Foster City, CA, USA) based on the sequences of mature miRNA downloaded from the miRNA registry database (http://miRNA.sanger.ac.uk).
All quantitative real-time PCR reactions were performed in a total volume of 30 μl. The PCR mix consisted of 1× PCR buffer (Mg 2+ free), 2.5 mM MgCl 2 , 0.3 mM dNTP, 1.5 U of rTaq DNA polymerase (TaKaRa), 0.33 μM Taqman probes, 0.33 μM each primer (Invitrogen), 17.1 μl ddH 2 O, and 1 μl of cDNA. The iCycler iQ System (Bio-Rad, Hercules, CA) was used as real-time PCR platform, and the PCR conditions for miRNAs and 5S rRNA were as follows: a single predenaturation step of 3 min at 94°C followed by 40 cycles of 20 s at 94°C and 40 s at 60°C. All reactions, including no-target control consisting of PCR master mix alone, were run in triplicate. To determine PCR efficiency, fivefold dilutions of colorectal cancer cell cDNA were done four times (1, 1:5, 1:25, 1:125, and 1:625). Both miRNAs and 5S rRNA gene in the diluted cDNA were amplified by realtime PCR using the identical conditions established for the gene expression analysis. Plots were made of the log of the template concentration vs the Ct, and the PCR efficiency was calculated by the iCycler iQ fluorescence PCR machine automatically from the slope of the line using Eq. 2 [20] : E ¼ 10 À1=slope ½ . The amplification curve and standard curve also were given at the same time. The 2 −ΔΔCT method of relative quantification was used for comparing the expression of miR-124 in tumor samples to matched normal mucosa samples [21] . First, the ΔC T between the C T values for target and reference genes for each tumor (t) and normal (n) sample were calculated:
The ΔΔC T for the tumor (t) and normal (n) was then calculated:
is the fold change of the miR-124 expression in the tumor sample relative to the normal sample, when normalized to the reference gene.
Quantitation of PCR products
The PCR products were subjected to electrophoresis on a 2 % agarose gel, to which ethidium bromide (10 mg/ml) had been added. Electrophoresis was carried out in Tris-borate-EDTA buffer at 120 V for 30 min. The bands were visualized under UV illumination, and a densitometer (Bio-Rad) was used to scan the intensity of the bands.
Statistical analysis
The relative expression analysis of miR-124 was performed by a randomization test using Relative Expression Software Tool (REST) 2009 (http://gene-quantification.com/rest-2009.html).
As for the 2 −ΔΔCT method, the fold change less than one in the expression was defined as decreased expression. The expression of miR-124 was assessed for associations with clinicopathological characteristics using chi-square test. The survival curves were calculated by the Kaplan-Meier method and the difference by the logrank test. The influence of each variable on survival was examined by the Cox multivariate regression analysis. All the analyses were performed with SPSS 18.0 software (Chicago, IL, USA). All P values cited were two sided, and P values <0.05 were judged as statistically significant.
Results
Expression of miR-124 in colorectal cancer and individual-matched normal mucosa
The expression of miR-124 was examined in 96 colorectal cancers and individual-matched normal mucosa samples. The amplification efficiency was 1.93 for 5S RNA and 1.89 for miR-124. No primer-dimer was generated during the 40 realtime PCR amplification cycles. Among 96 paired samples, 71 (73.9 %) cases showed the relative expression ratio (R) <1 which means miR-124 downexpression in those cancers. Fifty-six (58.3 %) cancers showed strong downregulated expression of miR-124 (more than twofold), of which 29 (30.2 %) cancers had more than ten times lower expression, and eight (8.3 %) cancers had >100 times lower expression, relative to the normal mucosa. To further compare the overall level of miR-124 expression in colorectal cancer relative to normal mucosa, we put the C T values of all the samples into the REST 2009 software and chose 3,000 as the randomization number. The results of the randomization test showed that miR-124 was significantly downregulated in colorectal cancer compared to normal mucosa (R00.390, P00.001, Table 2 ).
Relationship between expression of miR-124 and clinicopathological characteristics
The relationship between miR-124 expression and clinicopathological characteristics is shown in Table 3 . The expression of miR-124 differed significantly according to the grade of differentiation (P 00.021). There were 20 of 26 patients with downregulated level in poorly differentiated cancer samples, 39 of 47 in moderately differentiated, and 12 of 23 in well-differentiated cancer samples. No significant relationship was observed between the miR-124 expression and gender (P 00.618), age (P 00.977), location (P 00.690), maximum tumor size (P 00.992), depth of invasion (P 0 0.692), venous invasion (P 00.166), lymph node metastasis (P 00.618), distant metastasis (P 00.589), or TNM stage (P 00.236).
Relationship between expression of miR-124 and prognosis of colorectal cancer During follow-up, 43 patients died of colorectal cancer. Univariate survival analysis showed that the group with downregulated miR-124 was significantly correlated with worse prognosis, both in terms of overall survival (P0 0.017, Fig. 1 ) and disease-free survival (DFS) (P00.014, Fig. 2 ), than the upregulated group. Three-year overall survival and DFS were 88.0 and 76.0 % in the miR-124 upregulated group, but only 62.0 % and 47.9 % in the downregulated group. In the further Cox multivariate regression analysis, the prognostic significance still remained after adjusting for patients' gender, age, location, maximum tumor size, depth of invasion, differentiation, and TNM stage. Besides TNM stage, miR-124 was demonstrated an independent prognostic factor for overall survival (hazard ratio, HR04.634; 95 % confidence interval, CI, 1.731-12.404; P00.002; Table 4 ) and DFS (HR04.533, 95 % CI 1.733-11.856, P00.002, Table 5 ).
Discussion
Currently, a closer link between miRNA function and colorectal cancer pathogenesis is supported by a number of molecular studies examining the expression of miRNAs in clinical samples. With the investigation of these miRNAs, it would be conducive to expand our view to better understand colorectal carcinogenesis by analyzing mRNA targetassociated and miRNA-mediated pathways. As a potential tumor suppressor gene, miR-124 has been shown to regulate growth, proliferation, apoptosis, migration, and invasion of tumor cells in certain cancers [11, 14, 17, 20, 22] . The tumor-specific hypermethylation-mediated silencing of miR-124 was a relatively frequent molecular event in gastric, cervical, and breast cancer [11, 16, 17] . Moreover, some studies suggested that miR-124 has prognostic and therapeutic potential in hepatocellular cancer and non-small cell lung cancer [12, 13, 15] . In the research combining miRNA expression profiles with chromatin signatures, methylation of miR-124 was identified in colorectal cancer cell lines [23] . Although deregulation of miR-124 has been observed in various types of human cancers, due to our limited knowledge, the role of miR-124 in colorectal cancer is still unclear.
In this study, we observed that downregulation of miR-124 is a frequent event in colorectal cancer compared to normal mucosa, which is in line with the previous study that included 12 pairs of colorectal cancers and normal mucosa samples [24] . Lujambio et al [25] showed methylation-mediated Fig. 1 The expression of miR-124 in relation to overall survival in the patients with colorectal cancer Fig. 2 The expression of miR-124 in relation to disease-free survival in the patients with colorectal cancer silencing of miR-124 and concomitant reduced miR-124 expression in different human cancer types, reaching the highest frequency in colorectal cancer (75 %). In addition, this epigenetic dysregulation of miR-124 was proved to mediate cyclin D kinase 6 (CDK6) activation and retinoblastoma phosphorylation in HCT-116 colon cancer cells, and these processes can be restored by erasing DNA methylation. Based on the data derived from quantitative mass spectrometry [26] , the tumor suppressor gene IGFBP7 was identified as another target of miR-124 in colorectal cancer [27, 28] .
In line with previous research [29] , we indicated that the level of miR-124 expression was associated with the grade of differentiation. A lower expression of miR-124 was detected in moderately to poorly differentiated colorectal cancer. It has been shown that miR-124 plays an important role during neuronal differentiation and neural development [30] . By mediating inhibition of CDK6, which can regulate both cell cycle progression and differentiation [31] , the upregulation of miR-124 induced neuronal differentiation of brain tumor stem cells and inhibited proliferation of glioblastoma multiforme cell lines [29] . On the other hand, a recent research showing that knockdown of miR-124 promotes neuroblastoma cell differentiation, cell cycle arrest, and apoptosis indicated that miR-124 might exert diverse functions in differentiation of different cancers [32] . Thus, in agreement with these studies, our results may suggest that miR-124 plays a role in the differentiation of colorectal cancer. The further mechanism of the differentiation regulation for miR-124 in colorectal cancer should be explored in the future.
To the best of our knowledge, this is the first study to reveal the relationship between miR-124 and the prognosis of colorectal cancer. We showed that miR-124 was a significant predictor of overall survival and DFS and an independent prognostic factor for colorectal cancer. The similar conclusion was reported by Zheng et al. [15] -that lowlevel expression of miR-124 was an independent prognostic factor for poor outcome in hepatocellular cancer patients. MiR-124 modulated hepatocellular carcinoma cell aggressiveness by repressing the expression of ROCK2 and EZH2. The administration of miR-124 has been revealed to prevent and suppress hepatocellular carcinogenesis by inducing tumor-specific apoptosis without toxic side effects. MiR-124 may be a clinically viable anticancer therapeutic target for cancer [13] . Taking these results together, miR-124 potentially plays a tumor-suppressive function in the development and progression of colorectal cancer by negatively regulating its gene targets. The limitation of our study is that we have not analyzed the relationship between the expression of miR-124 and adjuvant therapy (chemoradiation or chemotherapy) for diverse regimens. As an important prognostic factor for colorectal cancer, adjuvant therapy could not be neglected. The prognostic significance of miR-124 in colorectal cancer patients receiving adjuvant therapy requires a further prospective controlled study. In conclusion, our results showed that miR-124 expression was significantly downregulated in colorectal cancer compared to normal mucosa. The expression of miR-124 differed significantly according to the grade of differentiation. A lower expression of miR-124 was detected in moderately to poorly differentiated colorectal cancer. Further, the downregulation expression of miR-124 is an independent prognostic factor in colorectal cancer patients. We believed that it is just the beginning of a long and still unexplored avenue of a highly promising investigation of miR-124. A more in-depth and larger-scale study remains to identify the role of miR-124 in colorectal cancer.
